Toyota|$17.83 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.97 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.55 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.93 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$513.40 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.86 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.38 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.27 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.40 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.63 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.40 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.62 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.50 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$465.73 (¥73,850)-2.29%▼ (in JPY terms)
Toyota|$17.83 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.97 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.55 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.93 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$513.40 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.86 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.38 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.27 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.40 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.63 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.40 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.62 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.50 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$465.73 (¥73,850)-2.29%▼ (in JPY terms)

DAIICHI SANKYO COMPANY,LIMITED

2026-09-28 DAIICHI SANKYO COMPANY,LIMITED “Regarding the voluntary withdrawal of the US application for approval of ifinatamab deruxtecan (I-DXd/DS-7300) for advanced small cell lung cancer (291.1KB) PDF file will be displayed in a new window.”

by

2026-09-28 DAIICHI SANKYO COMPANY,LIMITED “Regarding the voluntary withdrawal of the US application for … 続きを読む

2026-09-24 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) for postoperative drug therapy for HER2-positive early breast cancer (256.5KB) will open in a new window as a PDF file.”

by

2026-09-24 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

2026-09-16 DAIICHI SANKYO COMPANY,LIMITED “Notice of two partial amendments to the approval of the anti-cancer drugs "Enhertu®" and "Datroway®" for the first-line treatment of metastatic breast cancer in Japan (257.4KB) PDF file will be displayed in a new window.”

by

2026-09-16 DAIICHI SANKYO COMPANY,LIMITED “Notice of two partial amendments to the approval of the anti- … 続きを読む

2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for first-line treatment of non-small cell lung cancer with HER2 gene mutations, presented at the World Conference on Lung Cancer (WCLC 2026), will be displayed in a new window as a PDF file (282.8KB).”

by

2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzuma … 続きを読む

2026-09-01 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for the EU Regarding the First-Line Treatment of HER2-Positive Breast Cancer with Enhertu® (trastuzumab deruxtecan) and Pertuzumab (224.4KB) PDF file will open in a new window.”

by

2026-09-01 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for the EU Regarding the First-Lin … 続きを読む

Contact